News Updates
More Articles
- Benefits of Integrating Patient Engagement with Diversity, Equity, and Inclusion in New Medical Product Development: A Call for Action
- Drug Shortages in the Global South: A Proposed Parallel Tech and Reg Transfer Framework
- Fair Pay for Patient Engagement: Navigating the Evolving Landscape of Remuneration
- Industry’s Window to Express Interest in Africa Continental Product Evaluation Pilot Closes End of February 2024
- The Importance of Regulatory Due Diligence During the Acquisition Process
DIA China 2021: Global Pharmaceutical Regulation Evolving and Modernizing to Protect Public Health
The Global Regulatory Modernization Town Hall at DIA China 2021 aligned with the conference theme of Integrating into Globalization, New Journey to Innovation as representatives from four major regulatory authorities–the (China) National Medical Products Administration (NMPA), the US Food & Drug Administration (FDA), the European Medicines Agency (EMA), and the (Japan) Pharmaceuticals and Medical Devices Agency (PMDA)–shared strategies for building regulatory capacity building during the next three to five years.
×
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!